Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 1431-1435, April 1, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhatia, K.
Right arrow Articles by Magrath, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhatia, K.
Right arrow Articles by Magrath, I.

A Mutant p21 Cyclin-dependent Kinase Inhibitor Isolated from a Burkitt's Lymphoma

Kishor Bhatia1, Saijun Fan, Gordon Spangler, Michael Weintraub, Patrick M. O'Connor, Jean-Gabriel Judde and Ian Magrath

Lymphoma Biology Section [K. B., G. S., M. W., J-G. J., I. M.] and Laboratory of Molecular Pharmacology [S. F., P. M. O.], National Cancer Institute, NIH, Bethesda, Maryland 20892

The growth arrest mediated by p53 is caused at least in part by the p53 mediated expression of p21 (p21waf1/Cip1). Since only one-third of primary Burkitt's lymphomas (BL) demonstrate mutations in the p53 gene, we examined the structural integrity of the p21 coding region by single-strand conformational polymorphism and DNA sequence analysis to determine the extent to which this gene is mutated in BL. Of 34 BLs analyzed, a frequent change (38%) at codon 31 that replaced Ser with Arg was found in 13 samples, 10 of which were from Africa. This change at codon 31 is also detected in peripheral blood DNA from normal subjects and may thus represent a polymorphism. One BL cell line, DH978, carried a change at codon 63: Phe to Leu. This mutation was heterozygous, and both the wild-type and the mutated p21 mRNA were expressed in the tumor cell line. By transfection experiments, the mutant p21 was less efficient in suppressing clonogenicity than wild-type p21. To our knowledge, this is the only mutation described in p21. The availability of this mutant p21 should further help in functional studies of p21.

1 To whom requests for reprints should be addressed, at Lymphoma Biology Section, Bldg. 10/13C205, National Cancer Institute, NIH, Bethesda, MD 20892.

Received 12/16/94. Accepted 2/17/95.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
Y.-G. Xi, K.-Y. Ding, X.-L. Su, D.-F. Chen, W.-C. You, Y. Shen, and Y. Ke
p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions
Carcinogenesis, November 1, 2004; 25(11): 2201 - 2206.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Bellan, S Lazzi, G De Falco, A Nyongo, A Giordano, and L Leoncini
Burkitt's lymphoma: new insights into molecular pathogenesis
J. Clin. Pathol., March 1, 2003; 56(3): 188 - 192.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M J Schwerer, A Sailer, K Kraft, K Baczako, and H Maier
Patterns of p21waf1/cip1 expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas
J. Clin. Pathol., November 1, 2001; 54(11): 871 - 876.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
J. L. Gooch, R. E. Herrera, and D. Yee
The Role of p21 in Interferon {{gamma}}-mediated Growth Inhibition of Human Breast Cancer Cells
Cell Growth Differ., June 1, 2000; 11(6): 335 - 342.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
C. Cinti, L. Leoncini, A. Nyongo, F. Ferrari, S. Lazzi, C. Bellan, R. Vatti, A. Zamparelli, G. Cevenini, G. M. T osi, et al.
Genetic Alterations of the Retinoblastoma-Related Gene RB2/p130 Identify Different Pathogenetic Mechanisms in and among Burkitt’s Lymphoma Subtypes
Am. J. Pathol., March 1, 2000; 156(3): 751 - 760.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Harima, K. Harima, S. Sawada, Y. Tanaka, S. Arita, and T. Ohnishi
Loss of Heterozygosity on Chromosome 6p21.2 as a Potential Marker for Recurrence after Radiotherapy of Human Cervical Cancer
Clin. Cancer Res., March 1, 2000; 6(3): 1079 - 1085.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
P. P. McKenzie, S. M. Guichard, D. S. Middlemas, R. A. Ashmun, M. K. Danks, and L. C. Harris
Wild-Type p53 Can Induce p21 and Apoptosis in Neuroblastoma Cells But the DNA Damage-induced G1 Checkpoint Function
Clin. Cancer Res., December 1, 1999; 5(12): 4199 - 4207.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Guedez, L. Courtemanch, and M. Stetler-Stevenson
Tissue Inhibitor of Metalloproteinase (TIMP)-1 Induces Differentiation and an Antiapoptotic Phenotype in Germinal Center B Cells
Blood, August 15, 1998; 92(4): 1342 - 1349.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. Chin, J. Pomerantz, D. Polsky, M. Jacobson, C. Cohen, C. Cordon-Cardo, J. W. Horner II, and R. A. DePinho
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Genes & Dev., November 1, 1997; 11(21): 2822 - 2834.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Maestro, A. Gloghini, C. Doglioni, S. Piccinin, T. Vukosavljevic, D. Gasparotto, A. Carbone, and M. Boiocchi
Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21
Blood, April 1, 1997; 89(7): 2523 - 2528.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Qiu, H. J. Forman, A. H. Schonthal, and E. Cadenas
Induction of p21 Mediated by Reactive Oxygen Species Formed during the Metabolism of Aziridinylbenzoquinones by HCT116 Cells
J. Biol. Chem., December 13, 1996; 271(50): 31915 - 31921.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Balbin, G. J. Hannon, A. M. Pendas, A. A. Ferrando, F. Vizoso, A. Fueyo, and C. Lopez-Otin
Functional Analysis of a p21WAF1,CIP1,SDI1 Mutant (Arg94 right-arrow Trp) Identified in a Human Breast Carcinoma. EVIDENCE THAT THE MUTATION IMPAIRS THE ABILITY OF p21 TO INHIBIT CYCLIN-DEPENDENT KINASES
J. Biol. Chem., June 28, 1996; 271(26): 15782 - 15786.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.